AI-generated · cited to primary sources · not investment advice
Eli Lilly and Company Common Stock (LLY) Jun 2024 Filing Analysis
Where does growth come from?
R&D investment is accelerating as the company advances its late-stage pipeline, particularly in cardiometabolic health and neuroscience. R&D expenses rose 15% in the three-month period and 21% for the six-month period year-over-year, reflecting a deliberate strategy to reinvest high gross margins into future growth. (2 accelerating across 2 signals)
“Research and development expenses increased 15 percent and 21 percent for the three and six months ended June 30, 2024, respectively, driven by continued investment in our portfolio and our people.”
See the full cited Future Growth analysis of Eli Lilly and Company Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.